Pamela J. Craig and Dr. Paul B. Rothman Elected to Merck Board of Directors
July 28, 2015 3:15 pm ET
Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that Pamela J. Craig, retired chief financial officer of
Accenture, and Dr. Paul B. Rothman, dean of the medical faculty, vice
president for medicine of The Johns Hopkins University and chief
executive officer of Johns Hopkins Medicine, will join the company’s
board of directors, effective Sept. 1, 2015.
The addition expands the Merck board to 14 members. Ms. Craig will serve
as a member of the company’s audit committee, and Dr. Rothman will serve
as a member of the company’s research committee. They will both stand
for election by the company’s shareholders in May 2016.
“We are pleased to welcome Pamela Craig and Dr. Paul Rothman to the
Merck board. Each brings a tremendous wealth of experience and expertise
in their respective fields,” said Kenneth C. Frazier, chairman and chief
executive officer, Merck. “We are confident that their contributions and
insights will further strengthen the board.”
Ms. Craig served as the chief financial officer of Accenture, a global
management consulting, technology services and outsourcing company, from
2006 until her retirement in 2013. During her 34 years at Accenture, she
held a variety of consulting, line management, operational and finance
leadership roles. Ms. Craig is currently a senior advisor for Teneo, a
global advisory firm.
Ms. Craig is a Phi Beta Kappa graduate of Smith College and earned an
MBA from New York University. She serves as a member of the board of
directors of Akamai Technologies, a leading worldwide provider of
internet optimization services, where she also serves as audit committee
chair and as a member of the compensation committee. She also serves as
a board member and M&A committee member of VMware, Inc., a global
technology leader in virtualization and cloud infrastructure.
Additionally, Ms. Craig serves on the board of directors and audit
committee of Wal-Mart Stores, Inc.
Dr. Rothman oversees the Johns Hopkins Health System and school of
medicine. A rheumatologist and molecular immunologist, he joined Johns
Hopkins in July 2012 after having served as dean of the Carver College
of Medicine at the University of Iowa and leader of its clinical
practice plan since 2008. He previously served as head of internal
medicine at the University of Iowa from 2004 until 2008. Prior to that,
he was vice chairman for research and founding director of the Division
of Pulmonary, Allergy and Critical Care Medicine at Columbia University
College of Physicians and Surgeons, where he joined the faculty in 1986.
Dr. Rothman is a 1980 Phi Beta Kappa graduate of the Massachusetts
Institute of Technology and earned his medical degree from Yale
University in 1984. He is a member of the American Society for Clinical
Investigation and is a fellow of the American College of Physicians. He
was elected to the council of Association of American Physicians as a
fellow of the American Association for the Advancement of Sciences and
as a member of the American Clinical and Climatological Association.
Today’s Merck is a global health care leader working to help the world
be well. Merck is known as MSD outside the United States and Canada.
Through our prescription medicines, vaccines, biologic therapies and
animal health products, we work with customers and operate in more than
140 countries to deliver innovative health solutions. We also
demonstrate our commitment to increasing access to health care through
far-reaching policies, programs and partnerships. For more information,
and connect with us on Twitter,
Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA
This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the
“company”) includes “forward-looking statements” within the meaning of
the safe harbor provisions of the U.S. Private Securities Litigation
Reform Act of 1995. These statements are based upon the current beliefs
and expectations of the company’s management and are subject to
significant risks and uncertainties. If underlying assumptions prove
inaccurate or risks or uncertainties materialize, actual results may
differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry
conditions and competition; general economic factors, including interest
rate and currency exchange rate fluctuations; the impact of
pharmaceutical industry regulation and health care legislation in the
United States and internationally; global trends toward health care cost
containment; technological advances, new products and patents attained
by competitors; challenges inherent in new product development,
including obtaining regulatory approval; the company’s ability to
accurately predict future market conditions; manufacturing difficulties
or delays; financial instability of international economies and
sovereign risk; dependence on the effectiveness of the company’s patents
and other protections for innovative products; and the exposure to
litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise. Additional factors that could cause results
to differ materially from those described in the forward-looking
statements can be found in the company’s 2014 Annual Report on Form 10-K
and the company’s other filings with the Securities and Exchange
Commission (SEC) available at the SEC’s Internet site (www.sec.gov).
Lainie Keller, 908-236-5036
Justin Holko, 908-740-1879